Leerink Partnrs Has Weak Outlook for OmniAb FY2025 Earnings

OmniAb, Inc. (NASDAQ:OABI) – Research analysts at Leerink Partnrs cut their FY2025 EPS estimates for OmniAb in a note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst P. Souda now anticipates that the company will earn ($0.64) per share for the year, down from their prior forecast of ($0.63). The consensus estimate for OmniAb’s current full-year earnings is ($0.61) per share. Leerink Partnrs also issued estimates for OmniAb’s Q4 2025 earnings at ($0.15) EPS and FY2026 earnings at ($0.61) EPS.

OmniAb (NASDAQ:OABI) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01. The company had revenue of $10.80 million during the quarter, compared to the consensus estimate of $10.13 million. OmniAb had a negative net margin of 308.78% and a negative return on equity of 20.97%. During the same period in the prior year, the firm earned ($0.14) earnings per share.

A number of other equities research analysts have also recently weighed in on OABI. Benchmark cut their price objective on shares of OmniAb from $8.00 to $6.00 and set a “buy” rating on the stock in a report on Thursday. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of OmniAb in a report on Wednesday.

OmniAb Stock Performance

Shares of OABI opened at $2.53 on Friday. The stock has a market cap of $357.28 million, a PE ratio of -4.08 and a beta of -0.14. OmniAb has a fifty-two week low of $2.23 and a fifty-two week high of $5.63. The firm’s 50-day simple moving average is $3.34 and its two-hundred day simple moving average is $3.77.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC lifted its position in OmniAb by 321.5% during the third quarter. Barclays PLC now owns 143,215 shares of the company’s stock valued at $606,000 after purchasing an additional 109,236 shares during the period. FMR LLC lifted its position in OmniAb by 10.6% during the third quarter. FMR LLC now owns 138,813 shares of the company’s stock valued at $587,000 after purchasing an additional 13,324 shares during the period. Atria Investments Inc bought a new position in OmniAb in the third quarter worth approximately $148,000. Murchinson Ltd. bought a new position in OmniAb in the third quarter worth approximately $4,230,000. Finally, State Street Corp raised its position in OmniAb by 1.7% in the third quarter. State Street Corp now owns 2,031,676 shares of the company’s stock worth $8,594,000 after acquiring an additional 34,654 shares during the period. Institutional investors own 72.08% of the company’s stock.

Insider Activity

In other news, CEO Matthew W. Foehr sold 41,811 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total transaction of $135,467.64. Following the sale, the chief executive officer now owns 3,749,639 shares in the company, valued at $12,148,830.36. This represents a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director John L. Higgins purchased 125,750 shares of the business’s stock in a transaction dated Thursday, March 20th. The shares were purchased at an average price of $2.35 per share, for a total transaction of $295,512.50. Following the acquisition, the director now owns 2,762,887 shares of the company’s stock, valued at approximately $6,492,784.45. The trade was a 4.77 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 112,260 shares of company stock worth $376,601 over the last 90 days. 8.60% of the stock is currently owned by insiders.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.